<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[advisory committee and vaccine Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/advisory+committee+and+vaccine.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to advisory committee and vaccine]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5570/is_200701/ai_n23592800]]></link>
		<description><![CDATA[BETHESDA, Maryland, January 25 /PRNewswire/ --    BETHESDA, Maryland, January 25 /PRNewswire/ --  ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 25 Jan 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL®, Merck's Investigational Cervical Cancer Vaccine; If Approved, GARDASIL Will Be the First Cervical Cancer Vaccine in the U.S]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_May_18/ai_n26868319]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's FDA Vaccines and Related Biological Products Advisory Committee voted unanimously that the data from Phase II and Phase III clinical trials support the efficacy and safety of GARDASILR (quadrivalent human papillomavirus (Types 6,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 18 May 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[CDC Advisory Committee on Immunization Practices Unanimously Votes to Add ROTATEQ®, Merck's New Rotavirus Vaccine, to the Childhood Immunization Schedule]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Feb_21/ai_n26768599]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- -Merck & Co., Inc. announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices ACIP unanimously voted to recommend that all infants, starting at six to 12 weeks of age, be vaccinated with ROTATEQR (rotavirus vaccine, live, oral, pentavalent)...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 21 Feb 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/infant.html"><![CDATA[infant]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[FDA Advisory Committee Agrees That Clinical Data Support the Efficacy and Safety of Zostavax&#153;, Merck's Investigational Vaccine for Shingles, in Adults Aged 60 and Older]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_Dec_15/ai_n15949347]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's FDA Vaccines and Related Biological Products Advisory Committee agreed that the extensive data from clinical trials in more than 40,000 people support the efficacy and safety of ZOSTAVAXTM (zoster vaccine live (Oka/Merck)), the...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 15 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[FDA Vaccines Advisory Committee Unanimously Agrees That Clinical Data from 70,000-Infant Phase III Trials Support the Efficacy and Safety of ROTATEQ®, Merck's Investigational Vaccine for Rotavirus Gastroenteritis]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_Dec_14/ai_n15946236]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's FDA Vaccines and Related Biological Products Advisory Committee voted unanimously that the data from the Phase III clinical trials with 70,000 infants support the efficacy and safety of ROTATEQR (rotavirus vaccine, live, oral,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 14 Dec 2005 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/advisory+committee.html"><![CDATA[advisory committee]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
</channel>
</rss>
